Biomaterial Database

Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. 2010

James E Froeschle, and Michael D Decker

Scientific and Medical Affairs, Sanofi Pasteur, Swiftwater, PA 18370, United States. jim.froeschle@sanofipasteur.com

After a single injection of Typhim Vi (typhoid Vi polysaccharide vaccine), serum antibody concentrations were monitored for 3 years in 37 adults who resided where typhoid fever was not endemic. Anti-Vi antibody concentrations declined progressively during the study, to levels that support the current US recommendation for revaccination every 2 years.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011135	Polysaccharides, Bacterial	Polysaccharides found in bacteria and in capsules thereof.	Bacterial Polysaccharides
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000907	Antibodies, Bacterial	Immunoglobulins produced in a response to BACTERIAL ANTIGENS.	Bacterial Antibodies
D013997	Time Factors	Elements of limited time intervals, contributing to particular results or situations.	Time Series,Factor, Time,Time Factor
D014436	Typhoid-Paratyphoid Vaccines	Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.	Paratyphoid Vaccine,Typhoid Vaccine,Vaccines, Paratyphoid,Vaccines, Typhoid,Paratyphoid Vaccines,Typhoid Paratyphoid Vaccines,Typhoid Vaccines,Vaccine, Paratyphoid,Vaccine, Typhoid,Vaccines, Typhoid-Paratyphoid
D014481	United States	A country in NORTH AMERICA between CANADA and MEXICO.